Caribou Biosciences, Inc. Increase (Decrease) in Other Operating Assets
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Other Operating Assets of -$13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $50.00K.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$63.00K.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$1.61M, a 306.28% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $155.00K, a 95.01% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2025 was -$3.35M, a 185.13% decline from fiscal 2024.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2024 was $3.94M, a 8097.92% increase from fiscal 2023.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2023 was $48.00K, a 91.49% decline from fiscal 2022.
- Caribou Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2022 was $564.00K, a 78.48% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$13.00K 10-Q · filed 2026-08-13 | -$1.62M derived: sum of 3 quarters · filed 2026-08-13 | -$1.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$63.00K 10-Q · filed 2026-05-07 | -$1.67M derived: sum of 2 quarters · filed 2026-05-07 | -$1.52M derived: sum of 3 quarters · filed 2026-05-07 | -$2.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.45M derived: sum of 2 quarters · filed 2026-03-05 | -$2.87M derived: sum of 3 quarters · filed 2026-08-13 | -$3.35M 10-K · filed 2026-03-05 |
| 2025-09-30 | $155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.26M derived: sum of 2 quarters · filed 2026-08-13 | -$1.74M 10-Q · filed 2025-11-12 | -$961.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.90M 10-Q · filed 2026-08-13 | -$1.12M derived: sum of 3 quarters · filed 2026-08-13 | $1.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$479.00K 10-Q · filed 2026-05-07 | $301.00K derived: sum of 2 quarters · filed 2026-05-07 | $3.41M derived: sum of 3 quarters · filed 2026-05-07 | $3.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $780.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.88M derived: sum of 2 quarters · filed 2026-03-05 | $3.73M derived: sum of 3 quarters · filed 2026-03-05 | $3.94M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.95M derived: sum of 2 quarters · filed 2025-11-12 | $3.15M 10-Q · filed 2025-11-12 | $3.17M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $50.00K 10-Q · filed 2025-08-12 | $68.00K derived: sum of 3 quarters · filed 2025-08-12 | $217.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $209.00K 10-Q · filed 2025-05-08 | $227.00K derived: sum of 2 quarters · filed 2025-05-08 | $376.00K derived: sum of 3 quarters · filed 2025-05-08 | $319.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $167.00K derived: sum of 2 quarters · filed 2025-03-10 | $110.00K derived: sum of 3 quarters · filed 2025-03-10 | $48.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $92.00K derived: sum of 2 quarters · filed 2024-11-06 | $30.00K 10-Q · filed 2024-11-06 | $233.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$119.00K 10-Q · filed 2024-08-06 | $84.00K derived: sum of 3 quarters · filed 2024-08-06 | $119.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$62.00K 10-Q · filed 2024-05-07 | $141.00K derived: sum of 2 quarters · filed 2024-05-07 | $176.00K derived: sum of 3 quarters · filed 2024-05-07 | $15.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $238.00K derived: sum of 2 quarters · filed 2024-03-11 | $77.00K derived: sum of 3 quarters · filed 2024-03-11 | $564.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$126.00K derived: sum of 2 quarters · filed 2023-11-07 | $361.00K 10-Q · filed 2023-11-07 | $526.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $326.00K 10-Q · filed 2023-08-08 | $491.00K derived: sum of 3 quarters · filed 2023-08-08 | $491.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $487.00K 10-Q · filed 2023-05-09 | $652.00K derived: sum of 2 quarters · filed 2023-05-09 | $652.00K derived: sum of 3 quarters · filed 2023-05-09 | $382.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $165.00K derived: sum of 2 quarters · filed 2023-03-09 | -$105.00K derived: sum of 3 quarters · filed 2023-03-09 | $316.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$270.00K derived: sum of 2 quarters · filed 2022-11-08 | $151.00K 10-Q · filed 2022-11-08 | $151.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $151.00K 10-Q · filed 2022-08-09 | $151.00K derived: sum of 3 quarters · filed 2022-08-09 | $151.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $421.00K 10-Q · filed 2022-05-09 | $421.00K derived: sum of 2 quarters · filed 2022-05-09 | $421.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 derived: sum of 2 quarters · filed 2022-03-21 | $19.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $19.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $19.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $298.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |